Region:Global
Product Code:KR423
Ken Research announced its latest publication on "Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market" provides a comprehensive analysis of the glaucoma treatment drugs market. The report includes the market share contributed by the sales of generic and patented drugs globally for treatment of glaucoma. Further, the market in the study is differentiated by various parameters such as drug classes which include prostaglandin analogues, alpha agonist, beta blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications. On the basis of formulation, glaucoma treatment drugs market is categorized into topical eye drops, semisolid dosage forms and pills. The market is also segmented by six geographical regions across the globe - North America, Europe, Asia Pacific, Middle East, Latin America, and Rest of the World.
Detailed snapshot on key regions of the market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global glaucoma treatment drugs market and their respective shares by revenue in 2015. Analysis on pipeline products, patented drugs available in the market, and difference between generic and patented drugs is provided in the report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global glaucoma treatment drugs market has also been discussed along with recommendations from analyst view.
Global Glaucoma Treatment Drugs Market
Glaucoma being the second common cause of blindness globally has emerged as a worldwide problem. It was estimated that approximately ~ million people were affected with glaucoma worldwide in year 2013. The statistics clearly advocates the high demand for glaucoma treatment drugs across the globe. It has been estimated that glaucoma treatment drugs generated USD ~ million of revenue in 2010. However, the revenue declined at a high rate till 2013, owing to the expiry of major patented drugs including ~ and ~. Although as a result of increasing prevalence of glaucoma, the market experienced steady growth afterwards and the market was valued at USD ~ million in 2015. Aging population and rising awareness in the emerging economies owing to the efforts of the government and NGOs were the major reasons which assisted the market in its growth during this period.
Glaucoma Treatment Drugs Market Segmentation
On the basis of drug class, Prostaglandin analogues dominated the glaucoma treatment drugs market with revenue share of ~% in 2015 owing to its efficacy to treat glaucoma and presence of two high revenue generating patented drugs including Travatan Z and Lumigan. Additionally, high sales of off-patent drug Xalatan also help the segment in generating high revenue. Beta blockers with revenue share of ~% in 2015 followed prostaglandin analogues majorly due to high preference for these drugs in India and China.
By geographical regions, North America dominated the market with revenue share of ~% in 2015. High prevalence of glaucoma, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the glaucoma treatment drugs market in North America. Approximately ~ million people in the US were affected from glaucoma in 2015. Low cost of the drugs in Europe with strong reimbursement and high presence of patient pool in Asia Pacific regions helped these respective regions capture second and third position in the global glaucoma treatment drugs market. Europe captured ~% share, by revenue followed by Asia Pacific with revenue share of ~% in the global market in 2015.
Generic versus Branded Glaucoma Drugs
Glaucoma being a highly prevalent disease demands for effective and affordable treatment options. The launch of generic drugs in the market during the historical period, especially of ~ has resulted in decline in revenue share of patented drugs in the market from ~% in 2010 to % in 2015. Low cost of generic drugs is the major factor which has resulted in high adoption of generic drugs in the market. It has been observed that branded drugs cost approximately five times that of generic drugs. However, low efficacy of generic drugs restricts the ophthalmologists in prescribing generic drugs over patented drugs in economically stable countries. It has been noted that generic drugs show diverse bioequivalence with change in temperature. In addition to this bottle's material, shape, and size, delivery dose drop size, and different pH also impacts the efficacy of generic drug, resulting in more number of side effects and higher time frame treatment.
Competitive Scenario
Alcon dominated the glaucoma treatment drugs market in 2015 with revenue share of ~% owing to its wide range of products in its portfolio and high demand for its two patented drugs Simbrinza and Travatan Z. Allergan followed Alcon with revenue share of ~% in 2015. Wide distribution network in addition to patented product portfolio including Lumigan and Alphagen/Combigan assisted Allergan in gaining second position in the market. Pfizer Inc. and Akorn Inc. captured third and fourth position in the market respectively. High sales of off-patent drug Xalatan helped Pfizer in attaining respective position in the market.
Key Topics Covered in the Report:
Lumigan, Travatan Z, Combigan, Xalatan, Simbrinza Suspension, Azopt, Zioptan, Istalol, Cosopt PF, Vasneo, Rhopressa, Roclatan, Trabodenoson, Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Cholinergic, and Combination Medications
Alcon, Allergan plc, Akorn Inc., Bausch & Lomb Incorporated, Pfizer Inc, Merck & Co. Inc, Aerie Pharmaceuticals, Inotek Pharmaceuticals, Santen Pharmaceutical Co. Ltd
1. Executive Summary
Market Potential
Market Segmentation
Competitive Landscape
Generic versus Branded Glaucoma Drugs
Trends and Developments
Future Outlook and Projections
2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
2.3. Market Size and Modeling
Approach - Market Sizing
Market Sizing - Glaucoma Treatment Drugs Market
Limitations
3. Introduction
Types of Glaucoma
People at Risk
Symptoms of Glaucoma
Prevalence of Glaucoma
4. Global Glaucoma Treatment Drugs Market Size, 2010 - 2015
5. Global Glaucoma Treatment Drugs Market Segmentation
5.1. By Drug Class, 2015
5.2. By Formulations, 2015
5.3. By Geographical Regions, 2015
6. Snapshot on North America Glaucoma Treatment Drugs Market
6.1. United States
6.1.1. Prevalence of Glaucoma in the US
6.1.2. US Glaucoma Treatment Drugs Market
6.1.3. Patented Glaucoma Treatment Drugs Market in the US, 2015
6.1.4. US Glaucoma Treatment Drugs Market, by Drug Class
6.1.5. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Glaucoma Drugs Reimbursement Scenario in the US
6.2. Canada
6.2.1. Prevalence of Glaucoma in Canada
6.2.2. Canada Glaucoma Treatment Drugs Market
6.2.3. Cost Comparison of Glaucoma Drugs in the US and Canada
6.2.4. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
Pharmaceutical Pricing and Reimbursement in Canada
7. Snapshot on Europe Glaucoma Treatment Drugs Market
7.1. Prevalence of Glaucoma in Europe
7.2. Europe Glaucoma Treatment Drugs Market
7.3. Europe Glaucoma Treatment Drugs Market, by Drug Class
7.4. Europe Glaucoma Treatment Drugs Market, by Countries
7.5. Regulatory Landscape
7.5.1. New Drug Approval Procedure
7.5.2. Patents
7.5.3. Reimbursement Scenario in Europe
8. Snapshot on Asia Pacific Glaucoma Treatment Drugs Market
8.1. India
8.1.1. Prevalence of Glaucoma in India
8.1.2. India Glaucoma Treatment Drugs Market
8.1.3. India Glaucoma Treatment Drugs Market Segmentation by Drug Class, 2015
8.1.4. India Glaucoma Treatment Drugs Market, by Company
8.1.5. Regulatory Landscape
New Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India
8.2. People's Republic of China (China)
8.2.1. Prevalence of Glaucoma in China
8.2.2. China Glaucoma Treatment Drugs Market
8.2.3. China Glaucoma Treatment Drugs Market Segmentation by Drug Class, 2015
8.2.4. Regulatory Landscape
New Drug Approval Procedure
Patents
8.3. Japan
8.3.1. Prevalence of Glaucoma in Japan
8.3.2. Japan Glaucoma Treatment Drugs Market
8.3.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9. Global Glaucoma Treatment Drugs Market Competitive Landscape
9.1. Market Share of Glaucoma Drug Manufacturers in Global Glaucoma Treatment Drugs Market, 2015
9.2. Company Profiles for Key Manufacturers in Glaucoma Treatment Drugs Market
9.2.1. Allergan plc
9.2.2. Akorn, Inc.
9.2.3. Alcon
9.2.4. Bausch & Lomb Incorporated
9.2.5. Merck & Co. Inc.
9.2.6. Pfizer Inc.
10. Snapshot on Patented Glaucoma Treatment Drugs Market
11. Generic Versus Branded Glaucoma Drugs
12. Pipeline Analysis of Global Glaucoma Treatment Drugs Market
12.1. Phase III Drugs
12.2. Phase I and Phase II Drugs
12.3. Company Profiles
12.3.1. Aerie Pharmaceuticals
12.3.2. Inotek Pharmaceuticals
12.3.3. Santen Pharmaceutical Co. Ltd.
13. Trends and Developments in Global Glaucoma Treatment Drugs Market
13.1. Small Players Venturing into the Glaucoma Treatment Market
13.2. Acquisitions, Mergers, and Business Alliances
13.3. Unprecedented Medicare Cuts
13.4. Unawareness among Veteran Population
13.5. Rising Awareness Programs in Emerging Economies
13.6. Introduction of New Class of Drugs
14. Porter's Five Forces Analysis for Global Glaucoma Treatment Drugs Market
15. Future of Global Glaucoma Treatment Drugs Market
15.1. Future Outlook and Projections, 2016 - 2020
15.2. Cause and Effect Relationship between Dependent and Independent Factors Prevailing in Global Glaucoma Treatment Drugs Market
16. Analyst Recommendations
17. Macroeconomic Indicators
17.1. Aging Population
17.2. Number of People with Glaucoma
17.3. Glaucoma Surgical Devices Market
17.4. Emerging BRIC Economy
Disclaimer
Contact Us
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.